Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (I)



(I)

in which:

R^1 represents H or CH_3;

R^2 represents H, halogen, cyano, C1 to 2 alkyl, trifluoromethyl or C1 to 2 alkoxy;

n represents an integer 1, 2 or 3;

m represents an integer 0, 1, 2 or 3;

R^3 represents H, C2 to 4 alkenyl or C1 to 4 alkyl; said alkyl group being optionally further substituted by CN, C1 to 4 alkoxy, C1 to 4 alkyl–SO_2– or one or more fluoro atoms;

~~or R^3 represents a C1 to 4 alkylene group that forms a 4 to 7 membered azacyclic ring by virtue of being additionally bonded to either the aromatic ring, Ar, or to the linker group, $-CR^4R^5-(CR^4R^5)_n-$;~~

R^4 and R^5 independently represent H or C1 to 2 alkyl; ~~or the group CR^4R^5 together represents a 3 to 6 membered carbocyclic ring that optionally incorporates one heteroatom selected from O or S;~~ and each R^4, each R^5 and each group CR^4R^5 is selected independently;

Ar represents a phenyl ring ~~or a 5- or 6-membered heteroaromatic ring containing one to three heteroatoms selected independently from O, N and S~~; said phenyl ~~or heteroaromatic~~ ring being optionally substituted by one or more substituents selected independently from halogen, cyano, C1 to 2 alkyl, trifluoromethyl, C1 to 2 alkoxy, NR^6R^7, $-CONR^6R^7$, $-COOR^6$, $-NR^6COR^7$, $-S(O)_pR^6$, $-SO_2NR^6R^7$ and $-NR^6SO_2R^7$;

R^6 and R^7 independently represent H, C2 to 4 alkenyl or C1 to 4 alkyl; said alkyl or alkenyl groups being optionally further substituted by one or more halogen atoms;

p represents an integer 0, 1 or 2;

and pharmaceutically acceptable salts thereof.

2. (Original) A compound of formula (I), according to Claim 1, wherein n represents the integer 1.

3. (Previously presented) A compound of formula (I), according to Claim 1, wherein R^1 represents H.

4. (Cancelled)

5. (Previously presented) A compound of formula (I), according to Claim 1, in which each R^4 and each R^5 represents H.

6. (Previously presented) A compound of formula (I), according to Claim 1, in which m represents the integer 1.

7. (Previously presented) A process for the preparation of a compound of formula (I), according to Claim 1, which comprises:

(a) reaction of a compound of formula (II):



(II)

wherein R^1, R^2, R^3, R^4, R^5, Ar, m and n are as defined in Claim 1, with an isocyanate; or

(b) reaction of a compound of formula (III)



(III)

wherein R^1, R^2, R^4, R^5 and n are as defined in Claim 1 and LG represents a leaving group, with an amine ($R^3NH(CR^4R^5)_m$–Ar) wherein R^3, R^4, R^5, Ar and m are as defined in Claim 1; or

(c) reaction of a compound of formula (IV)



(IV)

wherein R^2, R^3, R^4, R^5, m, n and Ar are as defined in Claim 1,
with a compound of formula (V)



(V)

wherein R^1 is as defined in Claim 1 and LG represents a leaving group; or

(d) reaction of a compound of formula (VI)



(VI)

wherein R^2, R^3, R^4, R^5, m, n and Ar are as defined in Claim 1 and LG represents a leaving group,

with a compound of formula (VII)



(VII)

wherein R^1 is as defined in Claim 1;

and where necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting the resultant compound of formula (I) into a further compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

8. (Previously presented) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in Claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

9. (Previously presented) A pharmaceutical composition adapted for administration by inhalation or insufflation comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in Claim 1 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

10. (Previously presented) A process for the preparation of a pharmaceutical composition which comprises mixing a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in Claim 1 with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. (Cancelled)

12. (Cancelled)

13. (Currently amended) A method or the treatment or prophylaxis of inflammatory disease selected from the group consisting of asthma, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, chronic obstructive pulmonary disease, bone

resportive disease, osteoarthritis, and diabetes/glycaemic control; the method comprising administering to a person suffering from or at risk of said inflammatory disease a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in Claim 1.

14. (Previously presented) The method as claimed in Claim 13 wherein the disease is rheumatoid arthritis.

15. (Previously presented) The method as claimed in Claim 13 wherein the disease is chronic obstructive pulmonary disease.

16. (Cancelled)

17. (Currently amended) A method of treating, or reducing the risk of, cancer ~~a disease or a condition in which inhibition of IKK-2 activity is beneficial~~ which comprises administering to a person suffering from or at risk of said disease or condition a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in Claim 1.

18. (Cancelled)